Skip to Content

Giving patients treatment options

VIVUS is dedicated to meeting the needs and improving quality of life of patients with serious medical conditions and life-limiting diseases.

Our commercial products are indicated for the treatment of obese and overweight patients (Qsymia®) and exocrine pancreatic insufficiency (PANCREAZE®). According to the National Institutes of Health, overweight and obesity combined are the second leading cause of preventable death in the United States. Exocrine pancreatic insufficiency (EPI) affects many patient populations, including patients with cystic fibrosis, chronic pancreatitis, celiac disease, diabetes, both type 1 and type 2, inflammatory bowel disease and HIV infection.

Approved in the United States

PANCREAZE logo

PANCREAZE®

(pancrelipase) delayed-release capsules

PANCREAZE is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Warnings and Precautions:

PANCREAZE may increase your chance of having a serious, rare bowel disorder called fibrosing colonopathy that may require surgery. The risk of having this condition may be reduced by following the dosing instructions that your healthcare provider gave you. Take PANCREAZE exactly as prescribed by your doctor. Do not take more or less PANCREAZE than directed by your doctor.

Call your doctor right away if you have any unusual or severe stomach area (abdominal) pain, bloating, trouble passing stool (having bowel movements), nausea, vomiting, or diarrhea.


Qsymia logo

Qsymia®

(phentermine and topiramate extended-release) capsules CIV

Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30 kg/m2 or greater (obese) or
  • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia

Limitations of Use:

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.


REMS Program

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. The FDA has required a REMS for Qsymia. For more information visit:

Other Links & Resources

You are about to leave the VIVUS Inc. website

Links to third-party websites on VIVUS.com are provided solely for your convenience.

VIVUS Inc. does not control the content contained on any third-party website linked from this website. Activities on third-party websites will be governed by the policies and terms of use of those third parties.